Evidence map›Paper›PMID 42362943›Full record

GuidelineInternational journal of rheumatic diseases2026

2024 Update of the Asia-Pacific League of Associations for Rheumatology (APLAR) Recommendations for Rheumatoid Arthritis Management.

Kunihiro Yamaoka, Zhanguo Li, Khin Thin Zar Myo Aung, Paul Bird, Manisha Bhochhibhoya, Minhaj Rahim Choudhury, Debashish Danda, Tsolmon Darisuren, Rudy Hidayat, Nguyen Van Hung and 13 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in International journal of rheumatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Kunihiro YamaokaDepartment of Rheumatology, Kitasato University School of Medicine, Sagamihara, Japan.ORCID https://orcid.org/0000-0001-8858-9435
Zhanguo LiDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.ORCID https://orcid.org/0000-0002-2590-6242
Khin Thin Zar Myo AungDepartment of Rheumatology, Mandalay General Hospital, Mandalay, Myanmar.ORCID https://orcid.org/0009-0000-3902-8316
Paul BirdSchool of Clinical Medicine, University of New South Wales, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-2277-8337
Manisha BhochhibhoyaDepartment of Rheumatology, National Center for Rheumatic Diseases (NCRD), Kathmandu, Nepal.ORCID https://orcid.org/0000-0001-5075-7683
Minhaj Rahim ChoudhuryDepartment of Rheumatology, Bangladesh Medical University, Dhaka, Bangladesh.ORCID https://orcid.org/0000-0002-8695-5240
Debashish DandaDepartment of Clinical Immunology and Rheumatology, Christian Medical College, Vellore, India.ORCID https://orcid.org/0000-0002-2121-0942
Tsolmon DarisurenDepartment of Rheumatology, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.ORCID https://orcid.org/0009-0006-3906-4986
Rudy HidayatDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.ORCID https://orcid.org/0000-0003-4895-2409
Nguyen Van HungCentre for Rheumatology, Bach Mai Hospital - Department of Internal Medicine, Hanoi Medical University, Hanoi, Vietnam.ORCID https://orcid.org/0000-0003-0301-9471
Yuko KanekoDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0003-2646-5765
Wanruchada KatchamartDivision of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.ORCID https://orcid.org/0000-0002-8952-5967
Manjari LahiriDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID https://orcid.org/0000-0002-3482-6017
Chin Teck NgDepartment of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore.ORCID https://orcid.org/0000-0002-6396-1701
Babur SalimDepartment of Rheumatology, Foundation University School of Health Sciences, Fauji Foundation Hospital, Rawalpindi, Pakistan.ORCID https://orcid.org/0000-0001-8430-9299
Keshav Raj SigdelDepartment of Internal Medicine, Patan Academy of Health Sciences, Lalitpur, Nepal.ORCID https://orcid.org/0000-0002-0832-2579
Shereen Ch'ng SuyinRheumatology Unit, Selayang Hospital, Selangor, Malaysia.ORCID https://orcid.org/0000-0002-7436-2595
Tsutomu TakeuchiSaitama Medical University, Saitama and Keio University, Tokyo, Japan.ORCID https://orcid.org/0000-0003-1111-8218
Galymzhan TogizbayevJSC Research Institute of Cardiology and Internal Disease, Almaty, Kazakhstan.ORCID https://orcid.org/0000-0002-7842-1871
Evan VistaRheumatology, Allergy & Immunology Center, St. Luke's Medical Center, Quezon City, Philippines.ORCID https://orcid.org/0000-0002-6378-1049
Sandini WijeweeraDepartment of Rheumatology, District General Hospital, Negombo, Sri Lanka.
Chuanhui XuDepartment of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore.ORCID https://orcid.org/0000-0002-3222-7168
Chak Sing LauDivision of Rheumatology and Clinical Immunology, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.ORCID https://orcid.org/0000-0001-6698-8355

Funding

AbbVieGlaxoSmithKline
6 · The paper itself

Abstract

aimTo update the Asia-Pacific League of Associations for Rheumatology (APLAR) treatment recommendations for rheumatoid arthritis (RA) by incorporating new evidence and reassessing the validity of previous guidance:

methodsA literature search for relevant publications from January 2018 to August 2023 was conducted, supplemented by earlier studies where relevant. Recommendations were formulated based on this evidence and refined through a modified-Delphi process during a series of online meetings. The quality of evidence and strength of recommendations were assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach.

resultsThis update comprises 14 statements that achieved consensus during the meetings. Topics covered include measurement of disease activity and treatment response, the use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), the use of targeted therapies, vaccination and screening for infections and the use of DMARDs during pregnancy. The recommendations address the selection of disease activity scores, initiation and intensification of therapy using csDMARDs and targeted therapies, and management of RA in patients at risk of reactivation of infectious diseases. These recommendations are discussed in the context of the clinical landscape encountered in the Asia-Pacific region.

conclusionThese updated recommendations complement previous APLAR guidelines and aim to support best practice management of RA across the Asia-Pacific region. They provide a practical framework for national rheumatology associations to develop local guidelines adapted to their specific needs and clinical practice.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidRheumatologyAsiaConsensusFemaleHumansTreatment OutcomeAntirheumatic Agentsbiological DMARDdisease activityguidelinerheumatoid arthritistargeted synthetic DMARDs: conventional synthetic DMARDs

Identifiers

PMID42362943
PMCPMC13309519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.